Please login to the form below

Not currently logged in
Email:
Password:

cediranib

This page shows the latest cediranib news and features for those working in and with pharma, biotech and healthcare.

AZ withdraws EU filing for ovarian cancer drug cediranib

AZ withdraws EU filing for ovarian cancer drug cediranib

While its role as a monotherapy is ended, cediranib remains an important component of AZ's combination therapy strategy in ovarian cancer. ... This decision does not affect the ongoing primary development programme testing cediranib as a combination

Latest news

  • ASCO: AZ’s ovarian cancer combination aces trial ASCO: AZ’s ovarian cancer combination aces trial

    Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months. A combination therapy based on two AstraZeneca (AZ) compounds - olaparib and cediranib - has nearly doubled progression-free survival (PFS) compared ... Combining olaparib

  • Glioblastomas - a personalised future? Glioblastomas - a personalised future?

    Many agents have been unsuccessful. One of these, the pan-VEGF inhibitor cediranib, was discontinued at phase 3 due to disappointing results from pivotal studies.

  • Extending the arsenal

    It is also only one of a handful of therapies — along with aflibercept (Regeneron Pharmaceuticals), brivanib alaninate (Bristol-Myers Squibb) and cediranib (AstraZeneca) — in late-stage clinical trials for this type

  • AZ's Recentin trial disappoints

    AstraZeneca's colorectal cancer drug, Recentin (cediranib), has failed to match Roche's Avastin (bevacizumab) in a phase II/III comparison study. ... AstraZeneca (AZ) has announced that its colorectal cancer drug, Recentin (cediranib), has failed to

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics